Pharsight

Zetia patents expiration

ZETIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7030106 ORGANON Sterol absorption inhibitor compositions
Jan, 2022

(2 years ago)

US7030106

(Pediatric)

ORGANON Sterol absorption inhibitor compositions
Jul, 2022

(1 year, 8 months ago)

US7612058 ORGANON Methods for inhibiting sterol absorption
Oct, 2025

(1 year, 7 months from now)

US7612058

(Pediatric)

ORGANON Methods for inhibiting sterol absorption
Apr, 2026

(2 years from now)

Zetia is owned by Organon.

Zetia contains Ezetimibe.

Zetia has a total of 4 drug patents out of which 2 drug patents have expired.

Expired drug patents of Zetia are:

  • US7030106
  • US7030106*PED

Zetia was authorised for market use on 25 October, 2002.

Zetia is available in tablet;oral dosage forms.

Zetia can be used as to reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate; reduction of elevated plasma sterol and/or stanol levels in a mammal.

The generics of Zetia are possible to be released after 30 April, 2026.

Drugs and Companies using EZETIMIBE ingredient

Market Authorisation Date: 25 October, 2002

Treatment: To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate; Reduction of el...

Dosage: TABLET;ORAL

How can I launch a generic of ZETIA before it's drug patent expiration?
More Information on Dosage

ZETIA family patents

Family Patents